Update on multiple sclerosis therapies
The past decade has seen rapid advances in drug therapies for MS, each with their own side-effect profile.
MS is a heterogeneous, complex immune-mediated disorder of the central nervous system, affecting about 0.1% of the population in Australia.
The majority of people (85%) present with the relapsing-remitting form of MS, while others have a progressive disease. The relapsing phase is typified by inflammation and demyelination, while neurodegeneration predominates in the progressive